TOP > 外国特許検索 > NOVEL ANTI-PAD4 ANTIBODY

NOVEL ANTI-PAD4 ANTIBODY NEW

外国特許コード F190009933
整理番号 (S2018-0142-N0)
掲載日 2019年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP047871
国際公開番号 WO 2019131769
国際出願日 平成30年12月26日(2018.12.26)
国際公開日 令和元年7月4日(2019.7.4)
優先権データ
  • 特願2017-249589 (2017.12.26) JP
発明の名称 (英語) NOVEL ANTI-PAD4 ANTIBODY NEW
発明の概要(英語) An anti-PAD4 antibody that binds to active PAD4 or an anti-PAD4 antibody that inhibits the function of active PAD4 is achieved. An anti-PAD4 antibody is used which binds to active PAD4. Or, an anti-PAD4 antibody which binds specifically to a peptide formed from the amino acid sequence represented by sequence number 1, or an anti-PAD4 antibody which binds specifically to positions 633-644 of human PAD4 is used. This anti-PAD4 antibody optionally inhibits the citrullination activity of PAD4.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is PAD4(Peptidylarginine deiminase 4), citrulline arginine protein known as enzymes involved. This citrullinated is, most of the amino acids constituting the protein are highly basic and neutral where an arginine is converted to a reaction for citrulline, protein structure is important for the reaction.
PAD4 (RA) arthritis and rheumatoid arthritis to be involved in the pathology report indicating that there are several. For example, in Non-Patent Document 1, PAD4 with the development of RA gene single nucleotide polymorphisms and the correlation between the reported. Non-Patent Document 2 is, for the diagnosis of RA against the PAD4 antibody was used have been reported. Patent Document 1 is, 4 kinds of anti-PAD4 antibodies to mice by administering the mixture, an attempt to suppress the RA have been described. Is Patent Document 2, an anti-PAD4 antibody that binds to an epitope identified by administering a mouse, can be suppressed or arthritis RA have been described.
PAD4 Is, 'PAD4' and the 'active-inactive PAD4' is present. Ca2 + Is active and to bond, also referred to as Ca2 +-binding PAD4. Combining the non-active type is not Ca2 +, also referred to as the PAD4 Ca2 + non-bonded.
PAD4 And Ca2 + as reported, for example, Patent Document 3 exists. Patent Document 3 is, of rheumatoid arthritis patients and healthy serum amount PAD4, anti-PAD4 antibody is measured using ELISA described attempts. In the embodiment of Patent Document 3, when executing the ELISA, unprocessed serum using the appropriate measurement value cannot be obtained, and processing serum used EDTA an appropriate measurement value is obtained is described. At this time, as a result of the trap Ca2 + to EDTA, anti-PAD4 antibody that reacts with the non-active thought PAD4.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • YOKOHAMA CITY UNIVERSITY
  • 発明者(英語)
  • KANAZAWA, Satoshi
  • SATO, Mamoru
  • YAMADA, Michiyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close